Tyra Biosciences (TYRA) announced that a late-breaking abstract has been accepted for presentation at The Endocrine Society’s Annual Meeting, ENDO 2025, taking place July 12-15, 2025 in San Francisco, CA. Details of the poster presentation: Title: “TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Promising Outlook for Tyra Bioscience: Buy Rating Driven by TYRA-300’s Potential in NMIBC Treatment
- Tyra Bioscience Launches Phase 2 Study for TYRA-300
- Tyra Biosciences says first patient dosed in Phase 2 study of TYRA-300
- Tyra Biosciences up 3% as RA Capital increases stake to 22.4%
- Tyra Bioscience Holds 2025 Annual Stockholders Meeting